logo
Plus   Neg
Share
Email

Myriad Partners OptraHEALTH For AI-Based Information Tool Gene - Quick Facts

Molecular diagnostics company Myriad Genetics, Inc. (MYGN) announced Monday a new collaboration with AI platform OptraHEALTH to implement a cognitive ChatBOT named Gene to provide pre-test genetic and financial assistance information to prospective patients.

Gene is an AI-powered, HIPAA-compliant knowledge platform for genetic health with BOT interfaces and can answer over 500,000 health related questions pertaining to hereditary cancer.

Gene will interactively engage individuals online, providing them with education about hereditary cancer prior to taking an online assessment to determine if they may be a candidate for genetic testing. Gene can also assist in finding a healthcare provider who can help a patient make an informed, definitive decision.

Gene interfaces with Myriad's market leading online hereditary cancer quiz, which is now taken by approximately one million people per year.

Myriad plans on launching the Gene chatbot for its Foresight and Prequel prenatal tests and for companion diagnostic testing in oncology later this calendar year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Facebook has unveiled Instagram Reels as its answer to the popular Chinese-owned video app TikTok. The social media giant said in a blog post that Instagram Reels is a new way to create short, entertaining videos on Facebook's photo-sharing app Instagram. Facebook reportedly shut down its TikTok clone Lasso in July, ahead of the launch of Instagram Reels. WD-40 Company recalled about 130,000 units of X-14 Mildew Stain Remover for potential risk of skin irritation, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said pressure can build up inside the bottle and cause it to fall over and leak, posing a risk of skin irritation. Biopharmaceutical company Bristol-Myers Squibb Co. on Thursday reported a loss for the second quarter, compared to a profit last year, hurt primarily by hefty amortization expenses. However, adjusted earnings per share and quarterly revenues topped analysts' expectations. Looking ahead, the company raised its adjusted earnings and revenue outlook for the full-year 2020.
Follow RTT